C-0MX7Attralus
pan-amyloid removal, biologics, amyloid imaging
clearingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-0MX7
C-0MX7C-0MX7pan-amyloid removal, biologics, amyloid imaging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Recording of the Amyloidosis Support Groups webinar on Light Chain (AL) Amyloidosis on February 24, 2024. This webinar recording has been edited for content and time. Moderator: Muriel Finkel, President, Amyloidosis Support Groups Speakers: Angela Dispenzieri, MD, Chair, Division of Hematology, Mayo Clinic, Rochester, MN Suzanne Lentzsch, MD, PhD, Director, Multiple Myeloma and Amyloidosis Service, Professor of Clinical Medicine, Columbia University Medical Center, New York, NY *John Sekab, PharmD, Global Medical Director, Amyloidosis, Alexion, AstraZeneca Rare Disease, Boston, MA *Spencer Guthrie, Cofounder & Chief Operating Officer, Attralus, Inc., South San Francisco, CA *Ingrid Sprinz, PhD, Sr. Medical Director, Hematology, Prothena Biosciences, Brisbane, CA *Chetasi Talati, MD, Medical Director, Multiple Myeloma and Amyloidosis Clinical Development, AbbVie, North Chicago, IL Jonathan Wall, PhD, Program Director, Amyloidosis and Cancer Theranostics Program, and Professor, Tennes
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.
Dr. Jonathan Wall, Co-Founder and Interim Chief Scientific Officer at Attralus discusses the latest developments in systemic amyloidosis research, stemming from its oral and poster presentations at the XVIII International Symposium on Amyloidosis (ISA), alongside updates around its recently initiated Phase 1 trial in its lead therapeutic candidate, AT-02. #Attralus Jonathan Wall is a Professor at University of Tennessee Medical Center, Knoxville and Head of the Amyloidosis and Cancer Theranostics Program. Jonathan is an internationally known expert in the field of amyloidosis and has worked in the field of amyloidosis for over 25 years. He has over 100 publications and more than 13 issued US patents in this field. His research work was instrumental in the development of multiple antibody-based therapeutics that have undergone clinical development by biotech companies. His lab has received over $10M in NIH grant and contract funding for work that focuses on the development and
This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Jonathan Wall, PhD, Professor and Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program and Co-founder & Interim Chief Scientific Officer at Attralus, gives an overview of immunoglobulin light chain-associated (AL) amyloidosis. As Dr. Wall explains, AL amyloidosis is a rare blood disorder associated with the overproduction of amyloid, which leads to the deterioration of vital organs, most notably the heart, kidneys, and liver. The heterogeneity of this disease makes it difficult to diagnose and treat. There is no genetic predisposition for AL amyloidosis nor are there specific environmental factors associated with the disease. To learn more about AL amyloidosis and other rare blood disorders, visit checkrare.com/diseases/hematologic-disorders/.
Jonathan Wall, PhD, Professor and Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program and Co-founder & Interim Chief Scientific Officer at Attralus, explains why immunoglobulin light chain-associated (AL) amyloidosis is difficult to diagnose. AL amyloidosis is a rare blood disorder associated with the overproduction of amyloid, which leads to the deterioration of vital organs, most notably the heart, kidneys, and liver. The heterogeneity of this disease makes it difficult to diagnose and treat. There is no genetic predisposition for AL amyloidosis nor are there specific environmental factors associated with the disease. As Dr. Wall explains, the heterogeneity of the disease is one of the biggest barriers to swift diagnoses. Additionally, symptoms associated with AL amyloidosis include non-specific symptoms such as heart failure, renal insufficiency, and gastrointestinal issues. Gastroenterologists or GI specialists are mos
Jonathan Wall, PhD, Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program and Co-founder & Interim Chief Scientific Officer at Attralus, discusses data from a phase 1/2 trial evaluating the ability of AT-01 to detect amyloid deposits by PET/CT imaging in adults with a confirmed diagnosis of immunoglobulin light chain-associated (AL) amyloidosis. Data from this study were recently presented at The American Society of Hematology Meeting & Exposition (ASH 2021). AL amyloidosis is a rare blood disorder associated with the overproduction of amyloid, which leads to the deterioration of vital organs, most notably the heart, kidneys, and liver. As Dr. Wall explains, there are currently no approved methods in the United States for the non-invasive detection of amyloid distribution in patients with AL amyloidosis. To address this, Attralus developed the synthetic peptide radiotracer, AT-01, which is suitable for PET/CT imaging. Prec
This study is designed to assess the repeatability of organ-specific quantitation of radiotracer uptake following Positron Emission Tomography/Computed Tomography (PET/CT) imaging of AT- 01 in subjects with amyloid light chain (AL) or amyloid transthyretin (ATTR) systemic amyloidosis.
This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.
Heart Failure Management 2026: Precision Medicine to Personalize Care - UF CME - Continuing Education (CE) Cardiology</Profession" /> {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## << Back to UF CME Website Sign In Live Events On-Demand Grand Rounds QPSi Application Help {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## UF FACULTY & STAFF: If you have an active University of Florida GatorLink Account, click “Sign in with your UF credentials” below. Enter your UF username (GatorLink) and password on the UF authenticatio … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … lly Integrating Novel Drug Therapy in the setting of optimized EBM for CHF Best application of multiple types of devices to optimize outcomes and quality of life in CHF Promoting Close Partnerships with EP and Advanced HF Colleagues Emphasis on Integrated Team Approach to Optimize Delivery of CHF Care Our meeting is driven by expert faculty presentions and complemented by extensive panel discu... Amelia Island, FL false MM/DD/YYYY Date & Location Thursday, July 16, 2026, 11:0 … lly Integrating Novel Drug Therapy in the setting of optimized EBM for CHF Best application of multiple types of devices to optimize outcomes and quality of life in CHF Promoting Close Partnerships with EP and Advanced HF Colleagues Emphasis on Integrated Team Approach to Optimize Delivery of CHF Care Our meeting is driven by expert faculty presentions and complemented by extensive panel discussions and interactive audience involvement. We aim to describe successful integrati … aim to describe successful integration of current and novel drug therapies and application of multiple devices and invasive procedures to optimize outcomes and quality of life in patients with heart failure. Target Audience Specialties - Cardiology Professions - Nurse Practitioner, Physician (DO), Physician (MD), Physician Assistant Credits AMA
Attralus Inc. - BioCentury Company Profiles - BCIQ About BioCentury Privacy & Legal Contact About BioCentury Company Overview Management Editorial & Research Scientific Advisory Board Privacy & Legal User Agreement Terms of Use Privacy Policy Use of Images & Market Data Reprints & Permissions Contact Contact Us Advertising & Sponsorship Customer Resource Center Career Opportunities Forgot Password © 2026 BioCentury Inc. All Rights Reserved. Copyright © 2026 BioCentury Inc. All Rights Reserved.
Full Schedule Skip to main content Toggle navigation Login Search Home Tweets by 2022 PharmSci 360 Meeting Icon Legend This session is not in your schedule. This session is in your schedule. Click again to remove it. You are registered for this event. Additional Fee Advanced Content Attendee has chosen not to share their profile. --> Full Schedule Home Full Schedule All Days Fri, Oct 14 Sat, Oct 15 Sun, Oct 16 Mon, Oct 17 Tue, Oct 18 Wed, Oct 19 Thu, Oct 20 Full Schedule Type here to filter the list Friday, October 14, 2022 12:00 PM – 5:00 PM ET Registration Hours 12:00 PM – 5:00 P … Yawman, BS – DigiM Solution LLC ### 1689842###Rapid Fire Speaker###Senior Application Scientist###DigiM Solution LLC### Rapid Fire Speaker: Phillip D. Yawman, BS – DigiM Solution LLC ### 3:15 PM – 3:30 PM ET Coat Weight and Backing Membrane Effect on Adhesion of Patches Location:206 AB Rapid Fire Speaker: Oluwaseyi Salau, BS – Florida A&M University Manufacturing & Analytical Characterization – Chemical Favorite Oluwaseyi Salau, BS – Florida A&M … astri, PhD – Johnson and Johnson ### 8:30 AM – 9:00 AM ET Prologue: Application of PBPK Modeling to Support Dose Selection in Underrepresented Populations Prologue Speaker: Rodrigo Cristofoletti, PhD – University of Florida Clinical Pharmacology – Biomolecular 8:30 AM – 9:00 AM ET Prologue: Application of PBPK Modeling to Support Dose Selection in Underrepresented Populations Location:152 Prologue Speaker: Rodrigo Cristofoletti, PhD – University … D – Pfizer ### 9:30 AM – 10:00 AM ET Gene Efficiency Factor and its Application in the Development of Viral-Mediated in vivo Gene Therapy Location:254 A Speaker: Chee Meng Ng, PharmD, PhD, FCP – NewGround Pharmaceutical Consulting Preclinical Development – Biomolecular Favorite Chee Meng Ng, PharmD, PhD, FCP – NewGround Pharmaceutical Consulting ### 1650379###Speaker###Managing Director###NewGround Pharmaceutical Consulting### Speaker: Chee Meng Ng, Ph … ce, MSFS PhD FAACC – Capitainer AB ### 1602080###Keynote Speaker###Senior Application and Product Specialist###Capitainer AB### Keynote Speaker: Donald Chace, MSFS PhD FAACC – Capitainer AB ### @@@ Matthew S. Halquist, PhD – Virginia Commonwealth University ### 1447055###Moderator###Associate Professor and Laboratory Director###
Posters & Publications Archives | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact News Press Releases and Media All Posts Posters & Publications Press Releases In the News Renal and cardiac responses in a phase 1/2
%PDF-1.7 %���� 1 0 obj >/Metadata 440 0 R/ViewerPreferences 441 0 R/PageLabels 442 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Zms�6���dzӒ� &^� O:N��L�^�|��F�%���R Z�1�0*�$RQHr;¡��%��F�E���n�λ���Ӊ��^V���/���۹�w;� �kb���ohU8,a��r��N�X�X�+��y����u��s�8H�:Uq&���ɻ��� ���{�ӹߋ >�q�LJ5����9 �:���Z�|t\眏�k���q�s>:�s��ǵ���a���Y����V2��E4P�p�-`�`�x(�����!��i~w�%mϢ����.o S[s���^���แ�`&��bZ��+�5b�{/n�^ Fj�(\$(C�(;Y�ؒnK��Rb … i��4���wn��� Rf��&��risLb��h���sJ�Ы���p( F� � �[�:mƛs�H�^b ŻF�?Nx����� 0j�KZ���rFp~��J5���p��? "Ҭ�Q�Z|2,qyR=��'���F�/n��g�V�eΎm�$��� a����F���_��p�d,�]쿼��FG~�Z�~,k�ީ%�M�J&�� ���1 Z瑸ry zWM(T��ɤk�~ U�͎{���m��,g ��:�{װ|/�mm��^��O{���h�+��FA�����W �{[H�+Y��RI ��ʽ���3�n�>�����1�Z�b9~pc� ����g�w:�vA�H�Gw )���.������l�����)n�d�$ >�x���M�x��N�(�"�F���S����ˑ\��T9m���-n�5t���gA S��q)�:m��=z����v� �̖��к��ޜu��=bK�.��;� ���pr2rMo����p"_�� ����'�����ָ�EC��qԷsen�
Purastat Gel Instagram Log In Sign Up Purastat Gel Watch reels about purastat gel from people around the world. abbottglobal Verified views 15.5K It's official: Abbott and Exact Sciences have come together to transform how the world approaches cancer. Together we share a powerful purpose: helping people live fuller lives through better health. By expanding innovation and access to testing, we can detect and manage cancer when it is most treatable. Learn more in our link in bio. strykervisual... views 1,306 Introducing F88! Experience improved image quality, with consistent brightness with
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Science | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact OUR SCIENCE PROPRIETARY PAN-AMYLOID TARGETING TO TRANSFORM TREATMENT A NEW SCIENTIFIC PATH FORWARD Our proprietary pan-amyloid targeting agents are capable of treati
%PDF-1.4 %���� 3687 0 obj > endobj xref 3687 34 0000000016 00000 n 0000004088 00000 n 0000004266 00000 n 0000004303 00000 n 0000006823 00000 n 0000006936 00000 n 0000007051 00000 n 0000008950 00000 n 0000010935 00000 n 0000010964 00000 n 0000011482 00000 n 0000011933 00000 n 0000012186 00000 n 0000012321 00000 n 0000013124 00000 n 0000015053 00000 n 0000015512 00000 n 0000015925 00000 n 0000016184 00000 n 0000018048 00000 n 0000019970 00000 n 0000021859 00000 n 0000023791 00000 n 0000025593 00000 n 0000064837 00000 n 0000101336 00000 n 0000102188 00000 n 0000102259 00000 n 0000136417 00000 n 0 … 838C251FC56429 xmp.did:018011740720681197A5EE6408113C24 1 proof:pdf 58 AAAAAA== application/postscript 171029Logo_UKHD_dt_positiv_negativ_CMYK_RGB_sw.indd Sybille Adobe PDF Library 9.9 False PDF/X-4 PDF/X-4 1 False False 180.000038 179.999866 Millimeters Cyan Magenta Black Standard-Farbfeldgruppe 0 endstream endobj 4 0 obj > endobj 5 0 obj >stream application/pdf ern13-euroblood 2017-03-30T09:42:28+02:00 2017-03-30T09:42:28+02:00 2017-01-19T11:56+01:00 Adobe Illustrator CC 20 … 575-23a2bedc290a uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf converted from application/pdf to <unknown> saved xmp.iid:D27F11740720681191099C3B601C4548 2008-04-17T14:19:15+05:30 Adobe Illustrator CS4 / converted from application/pdf to <unknown> converted from application/pdf to <unknown> saved xmp.iid:F97F1174072068118D4ED246B3ADB1C6 2008-05-15T16:23:06-07:00 Adobe Illustrator CS4 / saved xmp.iid:FA7F1174072068118D4ED246B3ADB1C6 2008-05-15T17:10:45-07:0 … DDFD38D0CF24DD 2008-05-16T10:35:43-07:00 Adobe Illustrator CS4 / converted from application/pdf to <unknown> saved xmp.iid:F97F117407206811BDDDFD38D0CF24DD 2008-05-16T10:40:59-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to <unknown> saved xmp.iid:FA7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:26:55-07:00 Adobe Illustrator CS4 / saved xmp.iid:FB7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:29:01-07:00 Adobe Illustrator CS4 / saved … C1BF14D1759E83 2008-05-16T15:52:22-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:FA7F117407206811B628E3BF27C8C41B 2008-05-22T13:28:01-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:
Advances in Nuclear Cardiology, Cardiac CT and Cardiac MRI: 36th Annual Case Review with the Experts - Cedars-Sinai - Continuing Education (CE) The Advances in Nuclear Cardiology, Cardiac CT and Cardiac MRI: 36th Annual Case Review with the Experts will be held on January 20-22, 2023.&nbsp; &nbsp;</p><p><span style="font-size: 16px;">A major national healthcare imperative for noninvasive imaging is for the tests that are used provide value. Nuclear cardiology, cardiac CT and cardiac MRI studies provide powerful tools for diagnosis, risk assessment, and guiding manage … Your Password ?" link. Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … e patient radiation and contrast exposure while conducting high quality studies Apply optimal protocols for pharmacologic stress testing Create optimal reports that integrate test findings and provide guidance for patient management Identify the latest information regarding how test findings should be used to guide patient management decisions Use criteria and evidence-based strategies to reduce inappropriate testing Identify knowledge gaps regarding blueprints for the CBNC a … cation (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Additional Information Cedars-Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant fina … T|Consultant-Synektik Matthew Budoff, MD The Lundquist Institute Faculty Other: Grant recipient-GE Healthcare Bio-Sciences Tracy Q. Callister, MD Tennessee Heart & Vascular Institute Faculty Nothing to disclose Panithaya Chareonthaitawee, MD Mayo Clinic Faculty Consultant-Clario|Other: Royalties-UpToDate|Other: Speaker Fees-Ionetix|Other: Expert
Pathology Skills Enhanced with OPEN Program | Lewis Hassell posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … post In 2017, our team at EHRC, IIIT-B developed Sample Tracker, a specialized application designed for the Neuro Pathology Lab at NIMHANS to streamline and digitally manage laboratory workflows. Over the years, the system has actively supported neuro pathologists, technicians, and departmental staff in efficiently tracking and documenting laboratory activities - and it is now approaching 10 years of continuous real-world usage. Grateful to have contributed to a solution tha
Learner Notification | Society for Cardiovascular Magnetic Resonance Search for: Search for: Donate Join/Renew Login Language Search About Us Our Mission Board of Trustees Membership FSCMR MSCMR Committees Sections & Interest Groups Awards K-Space Store FAQ Contact Us Education Upcoming Events Past Events Training Verification & Certification Online Learning Cases of SCMR Course Endorsement Practice SCMR Initiatives CMR Center Directory Advocacy New to CMR Career Center Ask an Expert Publications SCMR Guidelines & Position Statements Journal of CMR (JCMR) NewsBeat News … fully passed quizzes. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit. By providing your information you grant SCMR permission to report your CME/MOC hours to the ACCME and/or other boards as applicable. Satisfactory Completion/CME/MOC To claim credit for a live SCMR CME event, you must complete the meeting evaluations. CME certificates will be provided upon … esearch as it applies to technical development and clinical applications in CMR Apply updated CMR techniques in the clinical setting DESIGNED to Change/Outcome : This CME activity is designed to change learner knowledge, competence and performance in the identification, diagnosis, and treatment of cardiovascular conditions following updated practice guidelines in CMR to lead to improved patient outcomes. Disclosure of Financial Relationships and Mitigation of Relevant Financi … to role(s) in the activity. Addetia, Karima Planning Committee Pfizer, Research Grant Site Principal Investigator The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. Allen, Bradley Planning Committee Imaging, Medscape, Guerbet, MRI Online, Consultant, Speakers Bureau, Research Grant Overall Principal Investigator, Private Stock Shareholder, Speakers Bureau The SCMR COI Subcommittee instructed recusal from planning … lanner, Chair, Co-Author, Moderator, Planning Committee GE Healthcare, Research Grant Site Principal Investigator The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. Ferreira, Vanessa Speaker, Chair, Planning Committee General Electric Healthcare, Research Grant Site Principal Investi
Novartis Announces Licensing Deals with PepLib and SciNeuro Pharmaceuticals | Susanne Kreutz posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to joi … eneration biologics therapeutics, on its strategic collaboration with Sanofi to apply Earendil’s discovery platform to multiple autoimmune and inflammatory disease programs. Congratulations to Earendil Labs and to the Cooley team led by Yiming Liu, Geoffrey Spolyar and Zack Gong . ➡️ Read more here: https://bit.ly/3LDxPaS 7 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Pharma Industrial India 9,657 followers 4mo Report this post Evoge … ies (NYSE: OSTX) announced that it has initiated the U.S. FDA Biologics License Application submission process for OST-HER2 in the prevention or delay of recurrent, fully resected pulmonary metastatic osteosarcoma. The company has submitted the non-clinical and Chemistry, Manufacturing, and Controls modules and requested a rolling review. At the FDA’s request, a Type D meeting is expected to review new comparative oncology biomarker data, with submission of the clinical modul … Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538, a VAV1-directed molecular glue degrader (MGD). This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. Read More Source link InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China https://dailynewsnblog.com Like Comment Share Copy LinkedIn Facebook X To view or add a
Heart Failure Management 2026: Precision Medicine to Personalize Care - UF CME - Continuing Education (CE) Cardiology</Profession" /> {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## << Back to UF CME Website Sign In Live Events On-Demand Grand Rounds QPSi Application Help {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## UF FACULTY & STAFF: If you have an active University of Florida GatorLink Account, click “Sign in with your UF credentials” below. Enter your UF username (GatorLink) and password on the UF authenticatio … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … lly Integrating Novel Drug Therapy in the setting of optimized EBM for CHF Best application of multiple types of devices to optimize outcomes and quality of life in CHF Promoting Close Partnerships with EP and Advanced HF Colleagues Emphasis on Integrated Team Approach to Optimize Delivery of CHF Care Our meeting is driven by expert faculty presentions and complemented by extensive panel discu... Amelia Island, FL false MM/DD/YYYY Date & Location Thursday, July 16, 2026, 11:0 … lly Integrating Novel Drug Therapy in the setting of optimized EBM for CHF Best application of multiple types of devices to optimize outcomes and quality of life in CHF Promoting Close Partnerships with EP and Advanced HF Colleagues Emphasis on Integrated Team Approach to Optimize Delivery of CHF Care Our meeting is driven by expert faculty presentions and complemented by extensive panel discussions and interactive audience involvement. We aim to describe successful integrati … aim to describe successful integration of current and novel drug therapies and application of multiple devices and invasive procedures to optimize outcomes and quality of life in patients with heart failure. Target Audience Specialties - Cardiology Professions - Nurse Practitioner, Physician (DO), Physician (MD), Physician Assistant Credits AMA
Market News & Trends Archives - Page 42 of 416 - Drug Development and Delivery You are using an outdated browser. Please upgrade your browser to improve your experience. SUBMISSION GUIDELINES ABOUT US BACK ISSUES MEDIA PLANNER CONTACT FREE PRINT SUBSCRIPTION Login --> --> Subscriptions Current/Back Issues/eBooks Market News & Trends Executive Interviews --> Select a Section Analytical Testing Bioavailability & Solubility Bio Platforms Drug Delivery Injection Devices Excipients Formulation Development Contract Services Market News & Trends Enable Injections Announces Regulatory … n Development, Market News & Trends Upperton Pharma Solutions Wins Champion Award at 2025 CDMO Leadership Awards in Small Molecule Dosage Form Category Upperton Pharma Solutions is proud to announce its selection as Champion Winner in the Small Molecule Dosage Form – International category at the 2025 CDMO… March 21, 2025 Contract Services, Formulation Development, Market News & Trends Traws Pharma’s Bird Flu Drug Candidate Presented at ICAR Traws Pharma, Inc. … rms, Formulation Development, Market News & Trends Dyadic Announces Funding Award to Use C1 to Accelerate Development of Protein-Based Vaccines Dyadic International, Inc. recently announced it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vaccines. CEPI is… March 20, 2025 Bio Platforms, Formulation Development, Market News & Trends Longeveron Announces Positive Type B Meeting With FDA Regarding Pathway to BLA fo … Late Stage Customization PCI’s Paul Smallman and Michelle D’Angelo explore the application and opportunities for leveraging advanced technologies in late stage customization and its potential to benefit pharmaceutical and biotech companies in gaining competitive advantage in their global supply chain. Learn More > A Guide to Aseptic Manufacturing The aseptic manufacturing process is complex with each drug candidate's unique set of challenges. Speed to market is necessary, … by WalkerTek . Don’t miss out on this exclusive content! Fill out the form and submit today Fill out the form below to access this exclusive content. --> Close this module
Edgewise Therapeutics, Inc. (Form: 8-K, Received: 04/02/2025) false 0001710072 0001710072 2025-04-02 2025-04-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 2, 2025   Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-40236   82-1725586 (State or other jurisdic … losing of the Registered Direct offering, which is expected to be sufficient to fund the Company's operations through 2028. This cash estimate is a preliminary estimate based on net proceeds and information available to management as of the date of this Current Report on Form 8-K. The Registered Direct Offering is expected to close on April 3, 2025, subject to the satisfaction of customary closing conditions.   The Shares in the Registered Direct Offering were offered pu … ck upon exercise of stock options and warrants described as outstanding in, the grant of options and awards under existing equity incentive plans described in, and the issuance of any stock upon conversion of the Company’s securities described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and the repurchase of shares of capital stock pursuant to agreements providing for an option to repurchase or a right of first refusal on behalf of … ion plans of the Company (the “Company Stock Plans”), (i) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, … ckholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any), to the Company’s knowledge, was duly executed and delivered by each party thereto, (ii) each such grant was made in all material respects in accordance with the terms of the Company Stock Plans, the Exchange Ac
AT-02 for Amyloidosis · Info for Participants · Phase Phase 1 Clinical Trial 2026 | Power | Power Share Search > Amyloidosis Apply to Trial Compensation: Varies Number of Visits: Unknown Share My employer runs this trial My employer runs this trial AT-02 for Amyloidosis (AT02-001 Trial) Not currently recruiting at 11 trial locations SS Overseen By Scott Stephens, RN Age: 18+ Sex: Any Trial Phase: Phase 1 Sponsor: Attralus, Inc. Must be taking: TTR silencers, stabilizers Disqualifiers: Pregnancy, Breastfeeding, Alcohol, others What You Need to Know Before You Apply What is the purpose of thi
UTRF Inventor Spotlight: Dr. Jonathan Wall - University of Tennessee Research Foundation Skip to main content Skip to footer University of Tennessee Research Foundation Technology Transfer & Licensing About Our Mission Foundation Details Student Opportunities Staff Subsidiaries Technologies Available Technologies Express Licensing For Innovators Accelerate Fund Resources IDEA Tutorial & Manuals Technology Transfer Process Business Incubator Technology Maturation Grant Funding Media News Newsletters Annual Reports Contact UT Ventures Search for: Search Button UTRF Administrator / Septe
Attralus Funding: How Much Did They Raise & Key Investors Products Product ZoomInfo Copilot AI sales agent GTM Workspace AI workspace for smarter GTM GTM Studio Build and run GTM workflows triggered by buying signals ZoomInfo MCP Connect your AI to verified B2B data Sales Company and contact database Marketing Actionable ABM platform Talent Source the best and brightest Operations Lead routing and data quality Data as a Service ZoomInfo data for your GTM systems Platform Cloud partners Ready, set, integrate Platform overview Connect industry-leading data across your entire tech stack Marke
%PDF-1.5 %���� 2 0 obj > endobj 23 0 obj > stream xuTMo�0 ��W�� �PEIǭ�a�е�� � �E8����Qr�8�� �HI�=>���=�-��%g� ���=|����>:�����镲�] 5�\� ��� O�x��.HJ��(rph�z�OFf%�� cr-��Le2{��:� `�,9�v�dcr���9�h�\P����R��- ��tp9�L�%�}��]����q��F�.�DQU;�h'��!趰��u�a�>�qT�^����O G�kx�J� '���;�";*/{�@w�JJ1�hG|�-�&������ԫ!i�� \��0V@� ֯�0^�f�@e�8b1�rxF?�L�2��� O�?��n� 6��t�t���c��.Xg�v���V���ۑK�������+��(�i�mWX�'�ͻ�ۯ+����+�6�� �~�����-n�^ 6#����^3>��� �M]xh��"��˼�N�.�u��R� ����cA��O����� ��\��U~�@� h���j�"XH��,B�E���٤��q��N endstream endobj 26 0 obj > stream x�X�r�F��+ … `� BH. a%�� N8�����\�*��s����W�j �P����y�Ț=��kmp�"Y�K�q�dg$ C^Ee���x�� �rFp�� ;g����0�l���1�|"�W�� �^%��-cW���i��� r�P��n �A�9'�W|M���d��x;ėV�f;����2�3��*���vi>���k�"�N��>�H�E�j���^ �d��S�A�ZĬ�$��Q��pX�I'���GG*�~W��� ����EƩ�[;%�%�Xd �� X�' ��Nk�W\�Ο�o,��wl$uG��� a$�r@� ��il��|���)����8 �h��(��(��(��������(��(�s�'�ލ���������ڜ/� ��;�:�0A��] !�������_�/�d��ë��t�)��k�0EͰ#̍I!@$�8�(��n���]�Yjcy,`)�{L;rP�$�k��Ƭ#��>��Y�Q���35η�}:�gc#I%�
Advancing Drug Development in ATTR - The Amyloidosis Forum Skip to content Main Menu Upcoming Meeting About Working Groups Endpoints Imaging Prognostic Factors Past Meetings Publications Advancing Drug Development in ATTR Amyloidosis in an Evolving Treatment Landscape June 21, 2023 | FDA White Oak Campus | Zoom Watch Meeting Recordings The first generation of drug approvals in ATTR amyloidosis has reshaped the research landscape creating the need to reconsider how to effectively design trials against a backdrop of treatments that slow progression of the disease. This Forum meeting will set the … ernal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, and a fellowship in cardiovascular magnetic resonance imaging at Beth Israel Deaconess Medical Center in Boston. He is Associate Chief of Cardiovascular Medicine for Academic Affairs, Associate Director of the Cardiovascular Medicine Fellowship program, and director of the cardiac MR program at BMC. Since 2017 he has directe … Amyloidosis Center, and Director of Nuclear Cardiology and the Cardiac Imaging Fellowship the at the University of Pittsburgh Medical Center (UPMC). After initial medical training in India, he was a clinical research fellow at the Northwick Park Hospital and Institute of Medical Research at Harrow, London, UK, where he obtained a PhD. His Cardiology and Advanced Imaging Fellowships in the US were at Tufts Medical Center, Boston, after which he joined the faculty at UPMC in 2 … clear Medicine and Molecular Imaging. He is a recipient of the Hermann Blumgart award for distinguished service to nuclear cardiology from the CV Council of the Society of Nuclear Medicine and Molecular Imaging in 2016 and the Outstanding Educator award in 2022. Preston Dunnmon, MD, MBA Moderator BIO+ Preston Dunnmon, MD, MBA × Moderator Dr. Preston Dunnmon received his medical degree from the Duke University School of Medicine, following which he completed his Internal … iversity School of Medicine, following which he completed his Internal Medicine residency and Cardiology fellowship at UT Southwestern Medical Center in Dallas. He was the recipient of an American Heart Association / Bugher Foundation Molecular Cardiology Fellowship, during which his research focus was G-protein mediated transmembrane signal tran
Bayer Positive Data for Investigational PET Radiotracer | Skip to main content X Search this site Eyebrow Menu About About Advertise Archive Contact Us ITN Awards Subscribe to newsletters Photo Galleries Blogs Blogs Blog Series Buyer's Guide Calendar Case Studies Comparison Charts Video Webinars Search this site Sign In New User? Register Here COVID-19 FDA Imaging 3-D Printing Angiography Computed Tomography (CT) Contrast media/injectors Digital Radiography (DR) Magnetic Resonance Imaging (MRI) Molecular Imaging Pediatric Imaging Radiation dose management Radiographic Fluoroscopy (RF) Ult
Bayer is acquiring two cardiac... - Cardiovascular Business Facebook Log In Cardiovascular Business's Post Cardiovascular Business January 13 · Shared with Public Bayer is acquiring two cardiac amyloidosis radiotracers from Attralus, one for PET and one for SPECT. The SPECT tracer is also a theranostic agent to both image and treat amyloidosis. #amyloidosis #Bayer #ThinkPET cardiovascularbusiness.com Bayer expands into molecular imaging with cardiac amyloidosis tracer acquisitions All reactions: 1 Like Comment
James Testa to Help Attralus in its Next Stage of Growth as its VP of Finance James Testa to Help Attralus in its Next Stage of Growth as its VP... 0 About Us Conference Advertise With Us Discovery CRO Drug Discovery and Development Laboratory Automation Pharma Tech Development & Manufacturing CMO Pharma Manufacturing Pharma Outsourcing Commercial Pharma Marketing Pharmacovigilance Leadership Perspectives Innovation Insights News Magazines CXO Awards Europe US EUROPE APAC Toggle navigation Freeze Drying System Biopharmaceutical Contract Manufacturing Toxicology Testing Medical Cannabis ×
NDV Genotype VII is now one of the most widespread and destructive velogenic strains worldwide, leading to severe outbreaks across the poultry industry and impacting both vaccinated and unvaccinated… | Francisco Monsalve LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choic
James Radke, Author at CheckRare Diseases Featured CME / CE Podcasts Resources Orphan Drug Approvals Priority Review Voucher Rare Disease Recognition and Awareness Days About Us Diseases Featured CME / CE Podcasts Resources Priority Review Voucher Tracking Rare Disease Recognition and Awareness Days 2026 Orphan Drugs: PDUFA Dates and FDA Approvals About Us Sign Up for our Newsletter Search for: Spotlight CAH Awareness Month Narcolepsy Gene Therapy for SMA Newsletter Newsletter Mechanism of Action of SRP-9001, A Gene Therapy For Duchenne Muscular Dystrophy by James Radke | Jan 5, 2023 Mechanism
Informative video from Dr. Jonathan... - Mackenzie's Mission Facebook Log In Mackenzie's Mission's Post Mackenzie's Mission April 2, 2023 · Shared with Public Informative video from Dr. Jonathan Wall of @Attralus describing their work to develop non-invasive imaging to diagnose amyloid deposits. Great stuff. #amyloidosis youtube.com New Method to Potentially Diagnose Amyloidosis All reactions: 10 1 comment 2 shares Like Comment Most relevant Susan Hulsey Watkins Excellent! The very end is the key - picking up amyloid deposits before any symptoms begin! Hooray!!! 3y 1
Pipeline | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Our Pipeline Pan-Amyloid Removal & Reversal Of The Underlying Pathology Of Systemic Amyloidosis Making New Solutions Possible for Patients AT ATTRALUS, WE SEE A
Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
AL Amyloidosis Market Report 2026 - Research and Markets Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert … e AL Amyloidosis Market Report 2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Attralus Announces Presentation of Clinical Data on AT-01, a Novel, Potential First-in-Class Diagnostic for Systemic Amyloidosis at the 2021 American College of Cardiology Annual Meeting | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Ca
University of Tennessee - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 12 May 2026 University of Tennessee Education | 1794 | Tennessee, United States | 5,000-10,000 | www.utk.edu Education | 1794 | Tennessee, United States | 5,000-10,000 | www.utk.edu Last update 12 May 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Digestive System Disorders Other Diseases Small molecule drug Herbal medicine Fusion protein Disease domain score A glimpse … sed Phase 2b/3 clinical trial following VisiRose’s pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration.” About VisiRose VisiRose is a clinical-stage biotechnology company focused on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT), an innovative ocular therapy developed at the Bascom Palmer Eye Institute's Ophthalmic Biophysics Center at the University of Miami Miller School of Medicine, which ranked No. 1 in oph … l of Medicine. Both scientists have been awarded the distinguished Orphan Dream Award in recognition of their contributions to advancing gene therapy for rare diseases. They will be formally recognized during the Resurrection premiere. Written by Patrick Girondi and directed by Brian Connors, the film reflects the broader scientific and personal journey behind these efforts. Connors, an experienced filmmaker, actor and producer, has built a career around independent storytell … ent storytelling grounded in real-world themes. The film stars Joe Mantegna, an award-winning actor known for his work in The Godfather Part III and Criminal Minds, and for his Tony Award-winning performance in Glengarry Glen Ross. The cast also includes Ronnie Marmo, known for his acclaimed stage work I’m Not a Comedian… I’m Lenny Bruce; Janelle Marmo, an actress and producer with television and independent film credits; Kathrine Kohl, a Danish-born actress and producer know … nown for Jacob the Baker; and Ian Fisher, an international actor, producer, and award-winning cinematographer with credits including The Lincoln Lawyer, Angelyne, and Leatherface. In parallel with the film’s release, P.G. Cuschieri will publish the related book, Resurrection of Cell and Gene Therapy, later this year. The book chronicles 14 years
Bayer acquires pan-amyloid radiotracers from Attralus | Nuclear Pharmacy Programs Skip to main content Toggle menu Home Professional Curriculum What is Nuclear Pharmacy? Nuclear Pharmacy Interview Series Nuclear Pharmacies in the US Home Professional Curriculum What is Nuclear Pharmacy? Nuclear Pharmacy Interview Series Nuclear Pharmacies in the US Bayer acquires pan-amyloid radiotracers from Attralus The agents include AT-01 (I-124 evuzamitide and in phase III) and AT-05 , labeled with technetium-99m and in phase I). https://www.auntminnie.com/clinical-news/molecular-imaging/news/15814419/bay
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. --> Accessibility: Skip TopNav Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis June 04, 2026 07:00 ET | Source: Attralus, Inc Attralus, Inc NAPLES, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for zamubafusp
Attralus Closes $116 Million Series B Financing --> Accessibility: Skip TopNav Attralus Closes $116 Million Series B Financing September 08, 2021 07:00 ET | Source: Attralus, Inc Attralus, Inc - Proceeds to advance pipeline of transformational pan-amyloid removal (PAR) therapeutics into the clinic - Financing led by Logos Capital and included other leading public healthcare funds - Appoints Alexander Denner, Ph.D., and Jake Bauer, to the Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developin
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA) | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Press Releases Attralus Presents
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
%PDF-1.4 1 0 obj > endobj 3 0 obj > endobj 4 0 obj [/Pattern /DeviceRGB] endobj 5 0 obj > endobj 12 0 obj > /ExtGState > /Pattern > /Font > /XObject > >> endobj 13 0 obj [ ] endobj 10 0 obj > stream x��]K������9�hŇ � �C�����C�� # ���nQj5� %R�n��v`� �b� �d��_>�3�������d_�ߏ�E^�E�';�܍/��߳��������k���zxm���}|��PW:?>#D������yu���^��<>���������Y,������� _~?|�v0'�-I�rkr�5�~q�)z�Z�tٱ ��U���3���#�?�x6�����yũ�� F ����v��ReRdo?g]Cw�_o�ը���U2{�)�� ��_��[S���Q�;�Q�;M.j��wt��>_)ɕ ҭOw�\��a��t�n�k2Ԣ���p��֎�:� ���z����{�A �K�u'�7 ��#��|�#��� �s葺��� ��C��u�Z��m�m$��{��tH�P e���"�kE
0001193125-23-098511.txt : 20230412 0001193125-23-098511.hdr.sgml : 20230412 20230412083056 ACCESSION NUMBER: 0001193125-23-098511 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20230523 FILED AS OF DATE: 20230412 DATE AS OF CHANGE: 20230412 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 4D Molecular Therapeutics, Inc. CENTRAL INDEX KEY: 0001650648 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473506994 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 A … ment, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Table of Contents 4D Molecular Therapeutics, Inc. 5858 Horton Street #455 Emeryville, CA 94608 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 2 … ors recommends that you vote FOR the election of the director nominees named in Proposal No. 1 of the Proxy Statement; and FOR the ratification of the appointment of PricewaterhouseCoopers LLP, as the independent registered public accounting firm, as described in Proposal No. 2 of the Proxy Statement. YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU PLAN TO ATTEND THE VIRTUAL ANNUAL MEETING, WE ENCOURAGE YOU TO READ THE ACCOMPANYING PROXY STATEMENT AND OUR ANNUAL REPORT O … D OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2022, AND SUBMIT YOUR PROXY AS SOON AS POSSIBLE USING ONE OF THE THREE CONVENIENT VOTING METHODS DESCRIBED IN THE “INFORMATION ABOUT THE PROXY PROCESS AND VOTING” SECTION IN THE PROXY STATEMENT. IF YOU RECEIVE MORE THAN ONE SET OF PROXY MATERIALS OR NOTICE OF INTERNET AVAILABILITY BECAUSE YOUR SHARES ARE REGISTERED IN DIFFERENT NAMES OR ADDRESSES, EACH PROXY SHOULD BE SIGNED AND SUBMITTED TO ENSUR … e?” 4 How many votes are needed to approve each proposal? 4 How many votes do I have? 4 What if I return a Proxy Card but do not make specific choices? 4 Who is paying for this proxy solicitation? 5 What does
UTRF Licensee Attralus Secures $25M in Investment - University of Tennessee Research Foundation Skip to main content Skip to footer University of Tennessee Research Foundation Technology Transfer & Licensing About Our Mission Foundation Details Student Opportunities Staff Subsidiaries Technologies Available Technologies Express Licensing For Innovators Accelerate Fund Resources IDEA Tutorial & Manuals Technology Transfer Process Business Incubator Technology Maturation Grant Funding Media News Newsletters Annual Reports Contact UT Ventures Search for: Search Button UTRF Administrator
Attralus Appoints Jake Bauer to Board of Directors | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Press Releases Attralus Appoints Jake Bauer to Board of Directors July 28, 2021 PDF Version Strengthens Board with seasone
Attralus to Present New AT-01 Data at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Press Releases Attralus to Present New AT-01 Data at 2022 Socie
Jie Zhou, USA | Chambers Profiles Skip to main content Submissions Login Rankings Rankings Regional Guides Asia-Pacific Brazil Canada Europe France Germany Global Greater China Region Latin America UK UK Bar USA USA: Spotlight Specialist Rankings Crisis & Risk Management FinTech High Net Worth Litigation Support NewLaw Related Profile Platform Build brand, drive growth. Amplify your ranking into the market. Contribute to an In-depth Overview Elevate your profile by positioning expert insights directly alongside ranking tables Purchase a Plaque A permanent symbol of independently validated … developing overall patent strategy to support their business objectives; patent application drafting; and prosecution of high value patent portfolios. Dr. Zhou has successfully obtained patent coverage for many therapeutic candidates that are in early development or in various phases of FDA approval. Dr. Zhou has significant experience in developing patent strategies and portfolios around breakthrough technologies in a wide spectrum of areas, including biologics (such as ther
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosi
Careers | Attralus | Mark Timney LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . … s Head of Program Management. ✳ Visit our website for additional details and to apply - https://lnkd.in/eW5gdPQV #joinourteam #hiring #amyloidosis ________________________________ Liked this post? Want to see more? 🔔 Sign up for alerts to be notified of our newest posts #️⃣ Follow - #Attralus 🌏 https://www.attralus.com Head of Project Management | Open Up New Possibilities For Your Career - Attralus https://attralus.com 24 1 Comment Like Comment Share Copy LinkedIn Facebook
Innovation - Page 231 of 910 - Pulse 2.0 VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Innovation Marksman Titan Security Acquires Priebe Security Services, Expanding Central Texas Footprint By Amit Chowdhry ● Jan 20, 2026 Marksman Titan Security Group has acquired Priebe Security Services, an Austin-based contract security provider, extending Marksman’s presence in Central Texas and adding more than 450 employees to its operations. Financial terms were not disclosed. Cordatus Capital Announces Red Dot Acquisition Of East Texas Architectural Sheetmetal By Amit C … ing, and servicing capabilities across its portfolio. Bansk Closes Continuation Fund To Extend Partnership With Arcadia Consumer Healthcare By Amit Chowdhry ● Jan 20, 2026 Bansk Group announced it has closed a continuation fund transaction to expand and extend its ownership partnership with Arcadia Consumer Healthcare, a fast-growing platform in over-the-counter medicines and premium vitamins and nutritional supplements. Ivo: $55 Million Series B Closed To Scale Contract Inte … ised $70 million in Series B funding led by Khosla Ventures and SoftBank Vision Fund 2, the company said Tuesday. Humans& Raises $480 Million Seed Funding At $4.48 Billion Valuation For Building Human-Centric AI Collaboration Tools By Amit Chowdhry ● Jan 20, 2026 Today humans& announced it officially launching, which is a new company founded by leading researchers from Google, Anthropic, xAI, OpenAI, Meta, and other top labs and academic institutions. In an announcement … eted an initial closing for its reconstruction-focused Horizon Capital Catalyst Fund and signed its first transaction: a partnership with Germany-based Notus Energy to finance a 124-megawatt wind power project in Ukraine’s Odesa region. TitanX: $27 Million Series A Raised To Scale The Phone Intent Category By Amit Chowdhry ● Jan 20, 2026 TitanX, a Knoxville, Tennessee-based sales intelligence company, announced it has raised a $27 million Series A round led by Updata Partners … deeper understanding of the company. Heitman Closes $2.62 Billion For Value-Add Fund VI By Amit Chowdhry ● Jan 20, 2026 Heitman has completed the final close of Heitman Value Partners Fund VI (HVP VI), securing $2 billion in fund commitments and an additional $620 million in co-investment capital. The close surpassed the fund’s $1.75 billion targ
Attralus Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Attralus Therapeutics Website: Attralus Therapeutics Business Area(s) Therapeutics Immunotherapy Description Attralus is developing novel pan-amyloid removal (PAR) therapeutics that directly bind to and remove toxic amyloid, opening the potential to treat and reverse disease in all types
Bayer Reports Positive Phase III Results for Investigational Cardiac Amyloidosis Imaging Agent --> Some Maintenance work will be going on. It will continue after 4PM. Sorry for Inconvenience. --> About Us About Leadership Advisory Board Clinipedia --> Glossary Terms --> Drug Development Process --> Therapeutic Area --> Sponsor/ Organisation --> Orphan Drug Designation --> Fast Track Approval --> Breakthrough Approval --> CRO --> --> --> Solutions Sources Subscription Contact Book Demo Free Trial --> Sign In --> Select Language All News Bayer Reports Positive Phase III Results for … today and make more informed sourcing decisions! Learn More! Leave Your Review Submit Comment --> Search Newsletter --> Latest Newsletter Post Helus Pharma Reports Strong Enrollm.. 25 June 2026 Ascletis Receives FDA Clearance to.. 25 June 2026 Advanta bioKEMIX and Resolkem Form.. 25 June 2026 Agomab Unveils Phase 2b Study Desig.. 24 June 2026 CureGene Doses First Patient in US.. 24 June 2026 Categories Product Related Updates Certificates/Accreditation Approval/Launch Clinic
Jeff Kelly, PhD | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Jeff Kelly, PhD Jeff Kelly, PhD SCRIPPS RESEARCH INSTITUTE Jeffery W. Kelly is Professor of Chemistry at The Scripps Research Institute. He is a leading expe
ATTR treatment landscape heats up as clinical progress gathers pace | The Pharmaletter Friday 26 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology
Get the job you really want - Zippia Verifying you are human. This may take a few seconds. (Loading widget...)
%PDF-1.4 %���� 1319 0 obj > endobj xref 1319 49 0000000016 00000 n 0000002308 00000 n 0000002471 00000 n 0000004179 00000 n 0000005370 00000 n 0000006561 00000 n 0000006710 00000 n 0000006739 00000 n 0000006891 00000 n 0000007006 00000 n 0000007095 00000 n 0000007244 00000 n 0000009301 00000 n 0000010639 00000 n 0000010731 00000 n 0000010858 00000 n 0000012907 00000 n 0000014250 00000 n 0000015395 00000 n 0000015544 00000 n 0000015643 00000 n 0000015792 00000 n 0000015919 00000 n 0000015958 00000 n 0000017119 00000 n 0000018128 00000 n 0000019089 00000 n 0000020142 00000 n 0000021216 00000 n 0 … Q�'��J�g� > endobj 1362 0 obj > endobj 1363 0 obj > endobj 1364 0 obj >stream application/postscript ARC-Logo-Development-round5 Renessa Ciampa Brewer 2018-04-02T14:51:45-04:00 2018-04-02T14:51:45-04:00 2018-04-02T14:51:45-04:00 Adobe Illustrator CC 22.1 (Macintosh) xmp.iid:8a44dd26-df2a-4a84-8250-f9fa5b09d650 xmp.did:8a44dd26-df2a-4a84-8250-f9fa5b09d650 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:72a72941-79bd-484b-8c0b-2284b1f335fc xmp.did:72a72941-79bd-484b-8 … 018-02-09T10:44:43-05:00 Adobe Illustrator CC 22.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:5d993cd9-49f1-454a-a989-0ba14b5c8f79 2018-03-01T08:55:19-05:00 Adobe Illustrator CC 22.0 (Windows) / … 2018-03-01T08:55:19-05:00 Adobe Illustrator CC 22.0 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:1f5abad9-60c5-6944-ac68-44e5a68f8380 2018-03-01T09:51:20-05:00 Adobe Illustrator CC 22.0 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:073cce86-00d8-4b5d-9e30-1240e7299216 2018-03-01T14:17:01-05:00 Adobe Illustrator CC 22.0 (Macintosh) / converted from application/postsc … dobe Illustrator CC 22.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:ea22196a-f02f-3c46-ab22-90aeab64d61e 2018-03-01T15:38-05:00 Adobe Illustrator CC 22.0 (Windows) / saved xmp.iid:8a44dd26-df2a-4a84-8250-f9fa5b09d650 2018-04-02T14:51:45-04:00 Adobe Illustrator CC 22.1 (Macintosh) / Print
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Attralus Acquired by Bayer | M&A News | Signalbase Signalbase Signals Pricing API docs Login Get API access Login Get API access Toggle menu M&A news · Published January 14, 2026 Bayer Acquires Attralus to Attralus acquired by Bayer Acquisition Hospitals and Health Care US Get the full Attralus company profile Access contacts, investors, buying signals & more Open in Dashboard Acquired Attralus United States Hospitals and Health Care Undisclosed amount January 14, 2026 Acquirer Bayer Bayer has acquired Attralus, a clinical stage biopharmaceutical company, for an undisclosed amount.
Extracardiac uptake of the SPECT/CT imaging agent, 99mTc-p5+14 (AT-05), in patients with AL or ATTR cardiac amyloidosis | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Posters & Publications Extracardiac uptake of the
alny-20251231 false 2025 FY 0001178670 http://www.alnylam.com/20251231#AccountingStandardsUpdate202507Member http://fasb.org/us-gaap/2025#DerivativeLiabilitiesCurrent http://fasb.org/us-gaap/2025#DerivativeLiabilitiesNoncurrent 0.0014923 0.0034941 1.5 33 1 245 247 275 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure alny:product alny:performance_obligation alny:day iso4217:USD alny:Unit alny:program alny:payment alny:facility alny:option alny:segment 0001178670 2025-01-01 2025-12-31 0001178670 2025-06-30 0001178670 2026-02-06 0001178670 2025-12-31 0001178670 2024-12-31 0001178670 u … 12 months (or for such shorter period that the registrant was required to submit such files).     Yes   ☑    No  ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “sm … es Food and Drug Administration, or the FDA, approved our supplemental New Drug Application, or sNDA, for AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. In June 2025, the European Commission, or EC, granted approval of AMVUTTRA for the treatment of wild-type or hereditary transthyretin amyloidosis in adu … se 2 development costs of zilebesiran. In February 2025, Blackstone opted in to fund up to $54.0 million of Phase 3 clinical trial development costs for zilebesiran. As consideration for Blackstone’s funding under the co-development agreement, we have agreed to pay Blackstone Life Sciences fixed success-based payments upon achievement of specific milestones for vutrisiran and zilebesiran, as well as a 1% royalty on net sales of vutrisiran for ten years. Please see Note … perty in our development programs or in collaborations, and Ionis agreed not to grant licenses under these patents to any other organization for the discovery, development and commercialization of double-stranded RNA products designed to work through an RNAi mechanism, except in the context of a collaboration in which Ionis plays an active role.
News Archives - Page 96 of 163 - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Partners – MassBio Partners – SCbio Get Involved FAQs CEO & Founder Link Align
Invest In Attralus Stock | Buy Pre-IPO Shares | EquityZen We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences Sign Up Today and Learn More About Attralus Stock Invest in or calculate the value of your shares in Attralus or other pre-IPO companies through EquityZen's platform. Get Started View More Companies Attralus Stock (ATTR) Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients. Invest Now Sell Shares About Attralus Stock Founded 2019 Headquarters San Francisco, CA … their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investmen … on FINRA’s BrokerCheck . EquityZen Inc. was awarded a 2024 Fintech Breakthrough Award by Tech Breakthrough LLC on March 19, 2025, based on the prior year and covering calendar year 2024, and has compensated FinTech Breakthrough LLC for use of its name and logo in connection with the award. FinTech Breakthrough LLC is a third party and has no affiliation with EquityZen. EquityZen created the ticker symbols referenced on this page for use solely on the EquityZen platform. They
News | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact News Press Releases and Media All Posts Posters & Publications Press Releases In the News Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug
Attralus, Inc. H-1B & PERM Sponsorship Data | Visa Bulletin U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support Attralus, Inc. H-1B & Green Card Sponsorship Data Source: US Dept of Labor. Represents Base Salary only. Excludes RSUs, signing bonuses, and variable compensation. View All Salary Records Search for another employer Years of Data Last 3 Years Last 5 Years Last 10 Years All Available Years Visa Program All Programs H-1B Only Green Card Only 1 Total Filings 2021-Present 0.0% Approval Rate Certi
Bayer Acquires Attralus Radiotracers, Expands into Molecular Imaging | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscribe
Careers | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Careers OPEN UP NEW POSSIBILITIES FOR YOUR CAREER Contact Us [email protected] COMPANY About Management Team Board of Directors Scientific Advisory Board I
Attralus Raises $116 Million to... - Amyloidosis Foundation Facebook Log In Amyloidosis Foundation's Post Amyloidosis Foundation September 18, 2021 · Shared with Public Attralus Raises $116 Million to Advance Pan-Amyloid Removal Therapeutics READ ABOUT IT HERE globalgenes.org Attralus Raises $116 Million to Advance Pan-Amyloid Removal Therapeutics - Global Genes All reactions: 35 2 comments 3 shares Like Comment Most relevant Patty Lippman Mona Lippman 4y 1 Mona Lippman Thanks Honey! 4y 2
Careers | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Careers OPEN UP NEW POSSIBILITIES FOR YOUR CAREER Contact Us [email protected] COMPANY About Management Team Board of Directors Scientific Advisory Board I
Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Press Re
Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents | oneAMYLOIDOSISvoice Skip to main content oAv Menu Home Patient Care Center Clinical Trials Providers Therapeutics People Places Community Center Community Stories Social Media Community Content Financial Assistance News Community Events Clinical Trials and Research Business News People Happenings Spotlight Fundraising Events Trusted Resources Education Videos & Visuals Event Calendar Login Search Home News Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents Bayer acquires Attralus’ cutting-edge
Jaume Pons, PhD | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Jaume Pons, PhD Jaume Pons, PhD CEO, ALX ONCOLOGY Dr. Pons is CEO of Alexo Therapeutics, a venture-funded Immuno-Oncology company co-founded and funded by ve
Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Press Releases Attralus Annou
Bayer Acquires Attralus for Cardiac Amyloidosis Imaging | Brian Casey posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Attralus, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Attralus, Inc. Startups | Holding Company | 2019 | California, United States | 10-50 | www.attralus.com Startups | Holding Company | 2019 | California, United States | 10-50 | www.attralus.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Attralus is a biopharmaceutical firm dedicated to developing innovative medications that can enhance … ase 2, and phase 2/3 is incorporated into phase 3 Discovery 1 1 Preclinical IND Application 1 2 Phase 1 Clinical Phase 2 Clinical 1 1 Phase 3 Clinical Other 1 Login to view more data Current Projects Drug(Targets) Indications Global Highest Phase Iodine (124I) evuzamitide Systemic amyloidosis More Phase 3 AT-02 (Attralus) ( APP x IgG ) Immunoglobulin Light-Chain Amyloidosis More Phase 2 AT-05(Attralus) Systemic amyloidosis More Phase 1 99mTc-p5+14 Systemic amyloidosis More Ph … hase 1 99mTc-p5+14 Systemic amyloidosis More Phase 1 AT-04 Amyloidosis More IND Application Login to view more data Deal Boost your decision using our deal data. login or view full example data Translational Medicine Boost your research with our translational medicine data. login or view full example data Profit Explore the financial positions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and
Attralus Closes $56 Million Financing – venBio Skip to content Home Team Portfolio Firm Press Contact Investor login Home Team Portfolio Firm Press Contact Investor login Investor login BACK Attralus Closes $56 Million Financing February 8, 2024 SAN FRANCISCO – February 06, 2024 – Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that it has closed a $56 million financing. The financing round was led by new investor Alpha Wave Ventures and also included Bristol M
Attralus Expands Access to Diagnosis with Bayer Partnership | Mark Timney posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives – venBio Skip to content Home Team Portfolio Firm Press Contact Investor login Home Team Portfolio Firm Press Contact Investor login Investor login BACK Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives May 10, 2021 Attralus, backed by venBio Partners, recruits new leadership team to support advancement of its pipeline to bring transformational pan-amyloid removal therapies to the systemic amyloidosis field May 10, 2021 07:00 AM Eastern Dayligh
Attralus Appoints Mark Timney as CEO and Expands Leadership Team with New Executives | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Press Releases Attralus Appoints Mark Timney as CEO and Expands Leadership Team with New
Mark Timney - Chief Executive Officer | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Mark Timney Mark Timney CHIEF EXECUTIVE OFFICER Mark Timney has deep experience in the biopharmaceutical industry. He has repeatedly di
Detection and Differentiation of Cardiac Amyloidosis Using [124]I-P5+14 PET/CT Imaging and the Correlation with Clinical Biomarkers | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Posters & Publications Detection and
Congratulations Jonathan Wall Spencer Guthrie and the entire Attralus team! Great news and I am happy for the amyloidosis imaging field to see that these products will be advanced into the clinical… | Sharmila Dorbala LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices
Company | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact ABOUT ATTRALUS DEEP EXPERIENCE IN AMYLOID RESEARCH, THERAPEUTIC DEVELOPMENT & COMMERCIALIZATION A COMPANY BRINGING NEW POSSIBILITIES Attralus aims to transform t
UTRF Licensee Attralus Secures $25M in Investment Funds for Advancements Related to Amyloidosis Research Led by Dr. Jonathan Wall ---> The University of Tennessee Health Science Center College of Medicine, Knoxville News Directories E-mail UT Medical Contact Us --> About Us Departments & Programs Medical Students Research Medical Library Medical Simulation Continuing Education News and Events UTRF Licensee Attralus Secures $25M in Investment Funds for Advancements Related to Amyloidosis Research Led by Dr. Jonathan Wall Jonathan Wall, PhD, and his amyloidosis research team have spent more than … ip Academy Announced Residents Recognized for Best in Research Cancer Institute Grant Endowment Supports Research Dr. Jeffrey Peeke Named Radiology Chairman UTRF Licensee Attralus Secures $25M in Investment Funds for Advancements Related to Amyloidosis Research Led by Dr. Jonathan Wall GSM Faculty Honored for Excellence UTGSM Faculty Promotions UTGSM New Faculty Spotlight Dr. Eric Heidel Receives Statistician Accreditation Professor Emeritus Dr. David Gerard's Memory Honored
Jonathan Wall, PhD | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Jonathan Wall, PhD Jonathan Wall, PhD CO-FOUNDER & INTERIM CHIEF SCIENTIFIC OFFICER Jonathan Wall is a Professor at University of Tennessee Medical Ce … linical development by biotech companies. His lab has received over $10M in NIH grant and contract funding for work that focuses on the development and translation of novel diagnostic and therapeutic reagents for amyloidosis. Back to Management team COMPANY About Management Team Board of Directors Scientific Advisory Board Investors SCIENCE Approach PAR Therapeutics PIPELINE NEWS Press Releases Posters & Publications AMYLOIDOSIS CAREERS CONTACT Privacy Policy Terms of Ser
Attralus Closes $116 Million Series B Financing | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Press Releases Attralus Closes $116 Million Series B Financing September 8, 2021 PDF Version Proceeds to advance pipeline of
Oral Presentations Archives | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL
Gregory Bell, MD | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Gregory Bell, MD Gregory Bell, MD CHIEF MEDICAL OFFICER Gregory Bell, M.D. earned his medical degree from Cornell University Medical College and completed h
Novel Pan-Amyloid Removal (PAR) Therapeutics | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact BRINGING NEW POSSIBILITIES TO AMYLOIDOSIS Attralus is developing novel pan-amyloid removal (PAR) therapeutics that directly bind
Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus | Attralus Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Home Company About Management Team Board of Directors Scientific Advisory Board Investors Science Approach PAR Therapeutics Pipeline News Press Releases Posters & Publications Amyloidosis Careers Contact Press Releases Bayer to expand into molecular imaging with acqui